From a molecular perspective, 18F-FDOPA PET’s ability to correlate with key genetic alterations and prognostic markers in GBM, such as IDH mutations, MGMT promoter methylation, and EGFR amplification, underscores its potential as a non-invasive biomarker. This evidence concerns the gene IDH2 and glioblastoma.